(Bloomberg) – CureVac, a German biopharmaceutical company, is in talks with the United States Governor, as well as other countries, about the summit of vacancies against the covid-19 of the last generation of various coronavirus fighters.
“By supuesto that we are dealing with EE.UU.”, said the executive director of pharmaceuticals, Franz-Werner Haas, in an interview with Bloomberg TV. It is “a very important market”.
CureVac will reveal the results of the vacancies with its ARN technology message in question and it is said that it is possible to receive the approval in the European Union before the end of the second quarter, as soon as possible. The company is based in Europe, Latin America and other countries in development with its current vacancy.
Preoccupation with the mutations
Without embargo, with the proliferation of mutated coronavirus viruses, there is even more concern that the first generation of vaccines could lose efficiencies and interrogators in order to provide the necessary vaccines for refueling to protect them.
The ultimate generation vehicle that CureVac is developing with GlaxoSmithKline will be able to allow the German company to recover land in EE.UU. about rivals BioNTech together with its company Pfizer, y Moderna. The vacancies produced by their companies have dominated the market since receiving the authorization for emergency use months ago.
CureVac, which has been working with ARNm technology for decades, has also benefited from the plants planted in the last weeks in relation to the method used by AstraZeneca and Johnson & Johnson for their vacancies, as well as the previous ones ARNm que le precedieron.
Also you can be interested:
VIDEO | Do you feel bad about being vaccinated against covid?
////
Note Original: CureVac is in talks with the US about the next generation Covid Shot
For more articles like this, please visit us at bloomberg.com
Join now to stay ahead of the most trusted business news source
© 2021 Bloomberg LP